Westminster-based Arca Biopharma is establishing a treatment for Covid-19

Arca Biopharma is in the process of developing a Covid-19 treatment.

The Westminster-based biotech company, which focuses on genetically targeted therapies for cardiovascular diseases, plans to submit its Investigational New Drug application with the U.S. Food and Drug Administration in September. The application is for AB201, a drug that has the potential to work as a treatment for severe Covid-19 patients, said Derek Cole, head of investor relations for the company.

AB201 is a drug that Arca…

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *


15 gadgets that will sell out in 2020